These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21135112)

  • 21. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
    Johnson FM; Saigal B; Talpaz M; Donato NJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation.
    Araujo JC; Poblenz A; Corn P; Parikh NU; Starbuck MW; Thompson JT; Lee F; Logothetis CJ; Darnay BG
    Cancer Biol Ther; 2009 Nov; 8(22):2153-9. PubMed ID: 19855158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
    Buettner R; Mesa T; Vultur A; Lee F; Jove R
    Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional analysis of Csk and CHK kinases in breast cancer cells.
    Bougeret C; Jiang S; Keydar I; Avraham H
    J Biol Chem; 2001 Sep; 276(36):33711-20. PubMed ID: 11445575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation.
    Wei J; Xu G; Wu M; Zhang Y; Li Q; Liu P; Zhu T; Song A; Zhao L; Han Z; Chen G; Wang S; Meng L; Zhou J; Lu Y; Wang S; Ma D
    Anticancer Res; 2008; 28(1A):327-34. PubMed ID: 18383865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
    Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
    J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
    Okamoto W; Okamoto I; Yoshida T; Okamoto K; Takezawa K; Hatashita E; Yamada Y; Kuwata K; Arao T; Yanagihara K; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 May; 9(5):1188-97. PubMed ID: 20406949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of androgen receptor activity by tyrosine phosphorylation.
    Guo Z; Dai B; Jiang T; Xu K; Xie Y; Kim O; Nesheiwat I; Kong X; Melamed J; Handratta VD; Njar VC; Brodie AM; Yu LR; Veenstra TD; Chen H; Qiu Y
    Cancer Cell; 2006 Oct; 10(4):309-19. PubMed ID: 17045208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
    Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.
    Mahajan NP; Liu Y; Majumder S; Warren MR; Parker CE; Mohler JL; Earp HS; Whang YE
    Proc Natl Acad Sci U S A; 2007 May; 104(20):8438-43. PubMed ID: 17494760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
    Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
    Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
    Migliaccio A; Di Domenico M; Castoria G; Nanayakkara M; Lombardi M; de Falco A; Bilancio A; Varricchio L; Ciociola A; Auricchio F
    Cancer Res; 2005 Nov; 65(22):10585-93. PubMed ID: 16288052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
    Park SI; Zhang J; Phillips KA; Araujo JC; Najjar AM; Volgin AY; Gelovani JG; Kim SJ; Wang Z; Gallick GE
    Cancer Res; 2008 May; 68(9):3323-33. PubMed ID: 18451159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paracrine Fibroblast Growth Factor Initiates Oncogenic Synergy with Epithelial FGFR/Src Transformation in Prostate Tumor Progression.
    Li Q; Ingram L; Kim S; Beharry Z; Cooper JA; Cai H
    Neoplasia; 2018 Mar; 20(3):233-243. PubMed ID: 29444487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer.
    Sen B; Peng S; Saigal B; Williams MD; Johnson FM
    Clin Cancer Res; 2011 Feb; 17(3):514-24. PubMed ID: 21106725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
    Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling.
    El-Sayed IY; Daher A; Destouches D; Firlej V; Kostallari E; Maillé P; Huet E; Haidar-Ahmad N; Jenster G; de la Taille A; Abou Merhi R; Terry S; Vacherot F
    Cancer Lett; 2017 Dec; 410():100-111. PubMed ID: 28935391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.
    Hessenkemper W; Roediger J; Bartsch S; Houtsmuller AB; van Royen ME; Petersen I; Grimm MO; Baniahmad A
    Mol Endocrinol; 2014 Nov; 28(11):1831-40. PubMed ID: 25203674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
    Rice L; Lepler S; Pampo C; Siemann DW
    Clin Exp Metastasis; 2012 Feb; 29(2):133-42. PubMed ID: 22130962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase.
    Asim M; Hafeez BB; Siddiqui IA; Gerlach C; Patz M; Mukhtar H; Baniahmad A
    J Biol Chem; 2011 Oct; 286(43):37108-17. PubMed ID: 21856747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.